STOCK TITAN

[8-K] Teladoc Health, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Teladoc Health, Inc. furnished an 8‑K to announce it issued a press release with its third‑quarter 2025 financial results. The press release is attached as Exhibit 99.1 and dated October 29, 2025.

The company states the information is being furnished, not filed under the Exchange Act, and therefore is not subject to Section 18 liabilities, nor incorporated into Securities Act filings unless specifically referenced.

Teladoc Health, Inc. ha fornito un 8-K per annunciare che ha emesso una comunicazione stampa con i propri risultati del terzo trimestre 2025. La comunicazione stampa è allegata come Esibizione 99.1 e datata 29 ottobre 2025.

La società afferma che le informazioni sono fornite, non depositate ai sensi della Securities Exchange Act, e quindi non soggette alle responsabilità della Sezione 18, né incorporate nelle registrazioni ai sensi del Securities Act a meno che non sia esplicitamente richiamata.

Teladoc Health, Inc. facilitó un 8-K para anunciar que emitió un comunicado de prensa con sus resultados del tercer trimestre de 2025. El comunicado de prensa está adjunto como Exhibit 99.1 y fechado 29 de octubre de 2025.

La compañía señala que la información se está proporcionando, no presentada conforme a la Ley de Intercambio, y, por lo tanto, no está sujeta a responsabilidades de la Sección 18, ni incorporada en presentaciones bajo la Ley de Valores a menos que se haga referencia específica.

Teladoc Health, Inc.은 8-K를 제공하여 2025년 3분기 재무 결과를 담은 보도자료를 발행했다고 발표했습니다. 보도자료는 Exhibit 99.1로 첨부되어 있으며 날짜는 2025년 10월 29일입니다.

회사는 이 정보가 Exchange Act에 따라 제공되었으나 제출은 아님으로 간주되며, 따라서 제18조의 책임에 적용되지 않으며 명시적으로 참조되지 않는 한 증권법(Securities Act) 제출서에 포함되지 않는다고 명시합니다.

Teladoc Health, Inc. a fourni un 8-K pour annoncer qu'il a publié un communiqué de presse présentant ses résultats du troisième trimestre 2025. Le communiqué est joint en tant qu'Exhibit 99.1 et daté du 29 octobre 2025.

La société déclare que les informations sont fournies, non déposées en vertu de la Exchange Act, et ne relèvent donc pas des responsabilités de la Section 18, ni ne sont incorporées dans les dépôts sous le Securities Act à moins d'être expressément référencées.

Teladoc Health, Inc. stellte eine 8-K bereit, um bekannt zu geben, dass eine Pressemitteilung mit den Ergebnissen des dritten Quartals 2025 veröffentlicht wurde. Die Pressemitteilung ist als Exhibit 99.1 beigefügt und datiert auf den 29. Oktober 2025.

Das Unternehmen gibt an, dass die Informationen bereitgestellt, nicht eingereicht werden nach dem Exchange Act und daher nicht den Haftungen gemäß Abschnitt 18 unterliegen, noch in Unterlagen gemäß dem Securities Act aufgenommen werden, es sei denn, darauf wird ausdrücklich verwiesen.

Teladoc Health, Inc. قد جرى تزويده بـ8-K للإعلان عن إصدار بيان صحفي يتضمن نتائجه المالية للـ الربع الثالث من 2025. البيان الصحفي مرفق كـ Exhibit 99.1 ومؤرخ في 29 أكتوبر 2025.

تذكر الشركة أن المعلومات يتم تزويدها، وليس تقديمها وفقًا لقانون التبادل، وبالتالي لا تخضع للمسؤوليات الواردة في القسم 18، ولا تُدرج في ملفات Securities Act إلا إذا تم الإشارة إليها صراحة.

Positive
  • None.
Negative
  • None.

Teladoc Health, Inc. ha fornito un 8-K per annunciare che ha emesso una comunicazione stampa con i propri risultati del terzo trimestre 2025. La comunicazione stampa è allegata come Esibizione 99.1 e datata 29 ottobre 2025.

La società afferma che le informazioni sono fornite, non depositate ai sensi della Securities Exchange Act, e quindi non soggette alle responsabilità della Sezione 18, né incorporate nelle registrazioni ai sensi del Securities Act a meno che non sia esplicitamente richiamata.

Teladoc Health, Inc. facilitó un 8-K para anunciar que emitió un comunicado de prensa con sus resultados del tercer trimestre de 2025. El comunicado de prensa está adjunto como Exhibit 99.1 y fechado 29 de octubre de 2025.

La compañía señala que la información se está proporcionando, no presentada conforme a la Ley de Intercambio, y, por lo tanto, no está sujeta a responsabilidades de la Sección 18, ni incorporada en presentaciones bajo la Ley de Valores a menos que se haga referencia específica.

Teladoc Health, Inc.은 8-K를 제공하여 2025년 3분기 재무 결과를 담은 보도자료를 발행했다고 발표했습니다. 보도자료는 Exhibit 99.1로 첨부되어 있으며 날짜는 2025년 10월 29일입니다.

회사는 이 정보가 Exchange Act에 따라 제공되었으나 제출은 아님으로 간주되며, 따라서 제18조의 책임에 적용되지 않으며 명시적으로 참조되지 않는 한 증권법(Securities Act) 제출서에 포함되지 않는다고 명시합니다.

Teladoc Health, Inc. a fourni un 8-K pour annoncer qu'il a publié un communiqué de presse présentant ses résultats du troisième trimestre 2025. Le communiqué est joint en tant qu'Exhibit 99.1 et daté du 29 octobre 2025.

La société déclare que les informations sont fournies, non déposées en vertu de la Exchange Act, et ne relèvent donc pas des responsabilités de la Section 18, ni ne sont incorporées dans les dépôts sous le Securities Act à moins d'être expressément référencées.

Teladoc Health, Inc. stellte eine 8-K bereit, um bekannt zu geben, dass eine Pressemitteilung mit den Ergebnissen des dritten Quartals 2025 veröffentlicht wurde. Die Pressemitteilung ist als Exhibit 99.1 beigefügt und datiert auf den 29. Oktober 2025.

Das Unternehmen gibt an, dass die Informationen bereitgestellt, nicht eingereicht werden nach dem Exchange Act und daher nicht den Haftungen gemäß Abschnitt 18 unterliegen, noch in Unterlagen gemäß dem Securities Act aufgenommen werden, es sei denn, darauf wird ausdrücklich verwiesen.

Teladoc Health, Inc. قد جرى تزويده بـ8-K للإعلان عن إصدار بيان صحفي يتضمن نتائجه المالية للـ الربع الثالث من 2025. البيان الصحفي مرفق كـ Exhibit 99.1 ومؤرخ في 29 أكتوبر 2025.

تذكر الشركة أن المعلومات يتم تزويدها، وليس تقديمها وفقًا لقانون التبادل، وبالتالي لا تخضع للمسؤوليات الواردة في القسم 18، ولا تُدرج في ملفات Securities Act إلا إذا تم الإشارة إليها صراحة.

Teladoc Health, Inc. 已提交一份8-K,以宣布其发布了包含其 2025年第三季度 财务业绩的新闻稿。该新闻稿作为 Exhibit 99.1 附件,日期为 2025年10月29日

公司声明信息是在根据交易法被提供,而非提交,因此不受第18条的责任约束,也不会在证券法的提交中被纳入,除非被明确引用。

FALSE000147744900014774492025-10-292025-10-29

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________
FORM 8-K
___________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported) October 29, 2025
___________________________________
Teladoc Health, Inc.
(Exact name of registrant as specified in its charter)
___________________________________

Delaware
(State or other jurisdiction of
incorporation)
001-37477
(Commission File Number)
04-3705970
(I.R.S. Employer Identification No.)
155 E 44th Street Suite 1700
New York, NY 10017
(Address of principal executive offices and zip code)
(203) 635-2002
(Registrant's telephone number, including area code)
___________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common stock, par value $0.001 per shareTDOCThe New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company    
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 2.02.    Results of Operations and Financial Condition.

On October 29, 2025, Teladoc Health, Inc. (the “Company”) issued a press release relating to its financial results for the third quarter of 2025. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1.

The foregoing information (including the exhibit set forth in Item 9.01 hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01.    Financial Statements and Exhibits.
(d) Exhibits.

Exhibit No.Description
99.1*
Teladoc Health, Inc. press release, dated October 29, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
* Furnished herewith.







SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 29, 2025
Teladoc Health, Inc.
By:
/s/ Adam C. Vandervoort
Name:
Adam C. Vandervoort
Title:
Chief Legal Officer and Secretary



Teladoc Health Inc

NYSE:TDOC

TDOC Rankings

TDOC Latest News

TDOC Latest SEC Filings

TDOC Stock Data

1.45B
175.40M
0.99%
74.28%
13.03%
Health Information Services
Services-offices & Clinics of Doctors of Medicine
Link
United States
NEW YORK